Evidence map›Paper›PMID 42226614›Full record

ArticleClinical and translational medicine2026

Multi-omics insights for deciphering prognosis-related T cell subsets in hepatocellular carcinoma.

Guangzu Cui, Erya Hu, Qingping Peng, Xin Zhou, Yu Zhao, Haicong Liu, Xinwen Wang, Yihong Chen, Hong Shen, Shan Zeng and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Guangzu CuiDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Erya HuDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Qingping PengDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xin ZhouDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yu ZhaoDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Haicong LiuDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xinwen WangDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yihong ChenDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Hong ShenDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.ORCID 0000-0002-6456-8231
Shan ZengDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Jiayao MaDepartment of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.

Funding

National Natural Science Foundation of China 82173342National Natural Science Foundation of China 82373275Natural Science Foundation of Hunan Province 2025JJ60506Wu Jieping Medical Foundation 320.6750
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is one of the leading causes of tumour-related death. T cells and cytokines play a critical role in tumour progression, but the T cell landscape correlated with HCC prognosis remains undepicted.

methodsThe prognostic significance of intra-tumoural immune cells, chemokines and cytokines were analysed using mass cytometry, bulk RNA sequencing and scRNA-seq data with survival information. The signature of CD4

findingsHigher intra-tumoural levels of DPT cells, CD45RA

conclusionOur findings depicted the prognostic immune landscape of HCC by identifying distinct T cell populations and molecular interactions. DPT cells emerged as a critical biomarker for poor prognosis, and the endothelial-derived HBEGF-DPT axis could represent a potential therapeutic target.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMultiomicsT-Lymphocyte SubsetsAnimalsAntibodies, Monoclonal, HumanizedBevacizumabHumansMaleMicePrognosisAntibodies, Monoclonal, HumanizedatezolizumabBevacizumabhepatocellular carcinomamulti‐omicsprognosisT cellstumour immune microenvironment

Identifiers

PMID42226614
PMCPMC13239885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.